Establishment of a severe aplastic anemia mouse model by using recombinant human interferon-gamma plus busulfan

doi:10.3969/j.issn.2095-4344.2014.36.022

Abstract

Abstract:

BACKGROUND: It is important to establish an ideal mouse model of severe aplastic anemia for investigating the mechanism and finding new therapies for aplastic anemia.
OBJECTIVE: To establish a severe aplastic anemia mouse model by using recombinant human interferon-γ and busulfan.
METHODS: Sixty healthy Kunming female mice were randomly divided into two groups: model group (n=50) and control group (n=10). The model group was given recombinant human interferon-γ at a dose of 1×10⁴ U/d by intraperitoneal injection and busulfan at a dose of 18 mg/(kg•d) through stomach feeding for 7 days. The same volume of physiological saline was given to control group. Multi-parameters, including general condition, body weight, blood cell count, morphology and biopsy of bone marrow were analyzed in two groups.
RESULTS AND CONCLUSION: At day 7 after treatment, the weight, white blood cell count, hemoglobin, blood platelet, reticulocyte count in model group were significantly lower than control group (P < 0.05). Bone marrow smears and biopsy of model group showed marked reduction of bone marrow proliferation and increases of percentages of non-hematopoietic cell clusters and adipose tissue. The oil drop and fat vacuole were apparently seen in the model group. Severe aplastic anemia mouse model can be established by using recombinant human interferon-γ and busulfan successfully, which is economic, stable and easy to operate.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: anemia, aplastic, model, mouse, interferon-γ

CLC Number:

R318

Liu Xiang, Zhong Shu-ping, Hou Li-jun, Xie Feng, Li Xue-gang, Pang Wen-zheng, Xu Jing-bo, He Zhi-guo. Establishment of a severe aplastic anemia mouse model by using recombinant human interferon-gamma plus busulfan[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(36): 5868-5873.

Figures/Tables 3

References

[1] Dolberg OJ, Levy Y. Idiopathic aplastic anemia: Diagnosis and classification. Autoimmun Rev. 2014.
[2] Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013;2013:76-81.
[3] Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196.
[4] Risitano AM, Perna F. Aplastic anemia: immunosuppressive therapy in 2010. Pediatr Rep. 2011;3 Suppl 2:e7.
[5] Marsh JC, Kulasekararaj AG. Management of the refractory aplastic anemia patient: what are the options? Blood.2013; 122(22):3561-3567.
[6] 李欣娜,李魏.骨髓抑制动物模型建立方法综述[J]. 黑龙江医药,2008,21(2):24-27.
[7] Gibson FM, Andrews CM, Diamanti P, et al. A new model of busulphan-induced chronic bone marrow aplasia in the female BALB/c mouse. Int J Exp Pathol. 2003;84(1): 31-48.
[8] 孙纪元,王四旺,谢艳华,等.再生障碍性贫血的动物模型实验研究[J].中国实验动物学杂志,2000,10(4):210-212.
[9] 黄永兰,黄绍良,蔡耘.骨髓间充质干细胞输注对再生障碍性贫血模型小鼠骨髓造血功能的影响[J].中国实验血液学杂志,2007, 15(5):1005-1008.
[10] 宁方颖,林赠华,刘红,等.干扰素-γ与白消安合用诱导建立小鼠重型再生障碍性贫血模型的研究[J].中华血液学杂志,2011,32(11): 777-782.
[11] 周志刚,吴文忠,陈亚峰,等.γ干扰素联合白消安诱导建立小鼠重型再生障碍性贫血模型中调节性T细胞的变化[J].广东医学, 2013, 34(2):184-186.
[12] 林庚庭,魏克民,张俊杰.再生障碍性贫血动物模型研究进展[J].浙江中西医结合杂志,2004,14(3):22-23.
[13] 卢玮,陈国安.免疫介导再生障碍性贫血动物模型的建立[J].实用临床医学,2010,11(10):124-126.
[14] 姚军,李树浓.淋巴细胞与再生障碍性贫血关系的实验研究[J]. 中华血液学杂志,1991,12(5):229-231.
[15] 潘景轩,朱振宇.免疫介导再生障碍性贫血小鼠血清诱导骨髓造血细胞凋亡及其机制初探[J].中华血液学杂志,1998,19(10): 510-513.
[16] Dufour C, Corcione A, Svahn J, et al. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol. 2001;115(4): 1023-1031.
[17] Maciejewski JP, Sloand EM, Nunez O, et al. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003;102(10):3584-3586.
[18] Nistico A, Young NS. gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1994;120(6):463-469.
[19] Li JP, Zheng CL, Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Crit Rev Oncol Hematol. 2010;75(2):79-93.
[20] de Bruin AM, Demirel O, Hooibrink B, et al. Interferon-gamma impairs proliferation of hematopoietic stem cells in mice. Blood. 2013;121(18):3578-3585.
[21] Welsh JP, Rutherford TR, Flynn J, et al. In vitro effects of interferon-gamma and tumor necrosis factor-alpha on CD34+ bone marrow progenitor cells from aplastic anemia patients and normal donors. Hematol J. 2004; 5(1):39-46.
[22] Dai C, Krantz SB. Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood. 1999;93(10):3309- 3316.
[23] Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375-386.
[24] Chatterjee S, Dutta RK, Basak P, et al. Alteration in marrow stromal microenvironment and apoptosis mechanisms involved in aplastic anemia: an animal model to study the possible disease pathology. Stem Cells Int.2010;2010: 932354.
[25] 赵英良,李建成,陈剑兵,等.γ-干扰素的研究及应用进展[J].江西畜牧兽医杂志,2009,28(1):6-9.
[26] 孙婷婷,徐文瑞,祝晓玲.再生障碍性贫血动物模型研究概况[J].中药药理与临床,2012,28(2):191-193.
[27] Hu X, Gu Y, Wang Y, et al. Increased CD4+ and CD8+ effector memory T cells in patients with aplastic anemia. Haematologica. 2009;94(3):428-429.
[28] Shi J, Ge M, Lu S, et al. Intrinsic impairment of CD4+CD25+ regulatory T cells in acquired aplastic anemia. Blood. 2012; 120(8):1624-1632.
[29] Kordasti S, Marsh J, Al-Khan S, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood. 2012;119(9):2033-2043.